Below are the financial statements of Genmab, including the income statement and balance sheet for the company's latest fiscal year. All figures are accurate, verifiable, and fully traceable to the original annual filing where disclosed.
| All figures in billions of DKK | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 21.53a | 16.47a | 14.51a |
| Cost of product sales | -0.99a | -0.23a | 0a |
| Research and development expenses | -9.75a | -7.63a | -5.56a |
| Selling, general and administrative expenses | -3.79a | -3.3a | -2.68a |
| Acquisition and integration related charges | -0.3a | 0a | 0a |
| Total costs and operating expenses | -14.82a | -11.15a | -8.24a |
| Operating profit | 6.7a | 5.32a | 6.27a |
| Financial income | 4.44a | 1.94a | 3.19a |
| Financial expenses | -1.98a | -1.62a | -2.51a |
| Net profit before tax | 9.16a | 5.64a | 6.95a |
| Corporate tax | -1.32a | -1.29a | -1.49a |
| Net profit | 7.84a | 4.35a | 5.45a |
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform. Explore Genmab’s data sources below and access millions more through our Disclosure Search.
Sign up for Tracenable and access millions of corporate disclosures, including annual reports and sustainability filings from global companies, completely free of charge.